| 【Company Research】Innovent Biologics (1801 HK) – Revenue growth to recover in 2023 |
| 【Company Research】BYDE (285 HK) – FY22 largely in-line; Gradual recovery on track |
| 【Company Research】Xiabu Xiabu (520 HK) – Both sales and margin recovery are on track |
| 【公司研究】阿里巴巴 (BABA US) – 组织变革或有望助力业务竞争力提升及估值重估 |
| 【公司研究】腾讯控股 (700 HK) – 2023微信公开课：微信生态持续高质量发展 |
| 【Company Research】Nongfu Spring (9633 HK) – Mid-teen top-line growth and a 90% dividend payout sustain the valuation premium over peers |
| 【Company Research】BYD Company (1211 HK) – Fair valuation despite FY22 high earnings quality |
| 【Company Research】Shenzhen Pagoda (2411 HK) – An ensuring 2022; and we remain positive for 2023 |
| 【Company Research】Kuaishou (1024 HK) – A solid start into 2023E |
| 【Company Research】China Feihe (6186 HK) – A 5%+ dividend yield looks attractive despite sluggish growth |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
